Terumo-2026-JPM.pdf

1、J.P.Morgan Healthcare Conference 2026Jan.12,2026Hikaru SamejimaChief Executive OfficerTerumo CorporationTERUMO CORPORATION 2 Forward-Looking Statements and Use of DocumentAmong the information that Terumo discloses,the forward-looking statementsincluding financial projections are based upon our assu

2、mptions using informationavailable to us at the time and are not intended to be guarantees of future events orperformance.Accordingly,it should be noted that actual results may differ from thoseforecasts or projections due to various factors.Factors affecting to actual resultsinclude,but are not lim

3、ited to,changes in economic conditions surrounding Terumo,fluctuations of foreign exchange rates,and state of competition.Information aboutproducts(including products currently in development)which is included in thismaterial is not intended to constitute an advertisement or medical advice.TERUMO CO

4、RPORATION 3 Precision built over the decadesTERUMO CORPORATION 4 60%20%20%Terumo at a GlanceNo.1 Medtech Company in JapanRevenueUSD 6.9 bnTBCT CompanyTMCS CompanyC&V CompanyFY24 Overseas Revenue Ratio:79%Business in over 160countries and regions Number of productsMore than52,000 Number of R&D basesJ

5、apan 6Outside of Japan 16 Number of production basesJapan7Outside of Japan 22 Terumo Interventional Systems Terumo Neuro Terumo Cardiovascular Terumo Aortic Hospital Care Solutions Life Care Solutions Pharmaceutical Solutions 1USD=150JPYTERUMO CORPORATION 5 01,0002,0003,0004,0005,0006,0007,000FY98FY

6、00FY02FY04FY06FY08FY10FY12FY14FY16FY18FY20FY22FY24Track Record of Robust GrowthM&A36%of sales,CAGR(FY99-24)16.1%Essen(China)Sales(M USD)CaridianBCT(US)MicroVention(US)Sequent(US)Bolton(US)Angio-Seal(US)OrganicCAGR(FY99-24)5.8%High single-digit revenue growth through M&AVascutek(UK)CardiovascularDiv.